Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone626-350-0537
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.36 million
Profitability
Miscellaneous
Employees123
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable
Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions
What is Fulgent Genetics' stock symbol?
Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics Inc (NASDAQ:FLGT) announced its quarterly earnings data on Monday, August, 5th. The company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The firm had revenue of $8.42 million for the quarter, compared to analyst estimates of $6.42 million. Fulgent Genetics had a negative net margin of 12.38% and a negative return on equity of 4.71%. View Fulgent Genetics' Earnings History.
When is Fulgent Genetics' next earnings date?
What price target have analysts set for FLGT?
2 analysts have issued 12 month price objectives for Fulgent Genetics' shares. Their forecasts range from $9.50 to $9.50. On average, they anticipate Fulgent Genetics' share price to reach $9.50 in the next twelve months. This suggests that the stock has a possible downside of 15.4%. View Analyst Price Targets for Fulgent Genetics.
What is the consensus analysts' recommendation for Fulgent Genetics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fulgent Genetics.
Has Fulgent Genetics been receiving favorable news coverage?
News coverage about FLGT stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fulgent Genetics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Fulgent Genetics.
Are investors shorting Fulgent Genetics?
Fulgent Genetics saw a increase in short interest in August. As of August 31st, there was short interest totalling 25,000 shares, an increase of 410.2% from the July 31st total of 4,900 shares. Based on an average daily trading volume, of 40,700 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.4% of the shares of the stock are sold short. View Fulgent Genetics' Current Options Chain.
Who are some of Fulgent Genetics' key competitors?
Some companies that are related to Fulgent Genetics include RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS), OpGen (OPGN), Cancer Genetics (CGIX) and Aeon Global Health (AGHC).
What other stocks do shareholders of Fulgent Genetics own?
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the folowing people:
- Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
- Mr. Paul Kim, Chief Financial Officer (Age 52)
- Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)
When did Fulgent Genetics IPO?
(FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.
Who are Fulgent Genetics' major shareholders?
Fulgent Genetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Mutual Advisors LLC (0.95%), River & Mercantile Asset Management LLP (0.84%), River & Mercantile Asset Management LLP (0.84%) and BlackRock Inc. (0.09%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.
Which major investors are selling Fulgent Genetics stock?
Which major investors are buying Fulgent Genetics stock?
How do I buy shares of Fulgent Genetics?
Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Fulgent Genetics' stock price today?
One share of FLGT stock can currently be purchased for approximately $11.23.
How big of a company is Fulgent Genetics?
Fulgent Genetics has a market capitalization of $207.64 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.
What is Fulgent Genetics' official website?
How can I contact Fulgent Genetics?
Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]
MarketBeat Community Rating for Fulgent Genetics (NASDAQ FLGT)
MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote "Outperform" if you believe FLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
